Evergreen Quality Fund GP Ltd. Makes New Investment in 4D Molecular Therapeutics, Inc. $FDMT

Evergreen Quality Fund GP Ltd. bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 951,474 shares of the company’s stock, valued at approximately $7,136,000. Evergreen Quality Fund GP Ltd. owned about 1.67% of 4D Molecular Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in FDMT. Dynamic Technology Lab Private Ltd bought a new stake in 4D Molecular Therapeutics during the 1st quarter valued at about $39,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics in the 3rd quarter worth about $41,000. AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics in the 1st quarter worth about $46,000. Rangeley Capital LLC purchased a new position in 4D Molecular Therapeutics during the 2nd quarter worth $48,000. Finally, Daiwa Securities Group Inc. grew its position in shares of 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares in the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

FDMT has been the subject of several recent research reports. Chardan Capital restated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Finally, Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.88.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $9.42 on Thursday. The stock’s 50-day moving average is $9.44 and its 200 day moving average is $9.14. 4D Molecular Therapeutics, Inc. has a 1-year low of $3.68 and a 1-year high of $12.34. The company has a market cap of $492.48 million, a P/E ratio of -3.67 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. On average, analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.